The Investigational Role of Stem Cell Transplantation (HSCT)

For many families, one of the most difficult decisions following an ALSP diagnosis is whether to pursue an allogeneic Hematopoietic Stem Cell Transplant (HSCT). This procedure, often called a bone marrow transplant, is an emerging, investigational option available for ALSP at specialized expert centers ^[1].

The theoretical goal of HSCT is to replace your own failing immune cells (microglia) with healthy donor cells that might support the brain’s white matter ^[2]. However, this is not an established standard of care. It is a high-stakes medical intervention with severe risks and a complex recovery process.

What the Preliminary Evidence Shows: Stabilization, Not Reversal

It is vital to understand that HSCT is not a “cure” that can fix damage that has already occurred. Current evidence is based mainly on small observational series and case reports with substantial selection bias. These reports suggest that a potential benefit of a transplant is stabilization—stopping or significantly slowing the further decline of the brain, rather than guaranteed disease modification ^[3][1].

• Mixed Results: In a specific cohort study of 17 adults, most survivors showed stabilization or slight improvement in their MRI scans and certain clinical symptoms by one year after the transplant ^[2].
• Early Worsening: In published reports, some patients experience a period of neurological worsening in the first six months following the procedure, which may represent a serious complication of the transplant rather than an expected phase ^[2][4].
• Selective Benefits: While walking (gait) and general function may stabilize in some, some symptoms—like parkinsonism (stiffness and tremors)—have continued to progress even after a successful transplant in some cases ^[4].

Identifying Candidate Profiles

Because the risks of HSCT are so severe, doctors are very selective about who should undergo the procedure. Current retrospective evidence suggests that certain factors are associated with better outcomes:

• Symptom Type: Patients whose symptoms began with walking or movement issues (gait-predominant) tend to have better outcomes than those whose first symptoms were significant cognitive or behavioral changes ^[1][5].
• Disease Stage: Younger patients and those who are still in the very early stages of the disease generally fare better ^[1].
• Cognitive Burden: If a patient already has significant cognitive impairment at the time of the transplant, they are at a higher risk for poor outcomes and further mental decline following the procedure ^[1].

Understanding the Severe Risks

HSCT is one of the most intensive procedures in medicine. It requires conditioning—using intense chemotherapy or radiation to clear out the existing bone marrow—which leaves the body extremely vulnerable ^[2]. A “myeloablative” conditioning regimen completely destroys the marrow, while a “reduced-intensity” regimen uses lower doses but still carries major risks.

Before proceeding, you must weigh these severe risks:

• Mortality: Procedure-related death is a serious risk. In one published 17-patient cohort, early mortality was roughly 12-15% ^[3][2]. This risk varies heavily by center, donor match, and conditioning regimen.
• Severe Infections: Because the immune system is “reset,” you are at high risk for life-threatening bacterial and fungal infections, such as Aspergillus (a serious lung infection), even with preventative medications ^[6][4].
• Graft-Versus-Host Disease (GVHD): This is a complication where the donor’s immune cells attack the patient’s body. While the frequency in reported ALSP cases may look low, chronic GVHD is a serious potential risk that can cause lifelong immune dysfunction ^[4].
• Neurological Complications: Some patients have developed new-onset seizures or experienced rapid neurological decline immediately following the procedure ^[4].
• Long-term Toxicities: Conditioning can cause prolonged hospitalization, severe mucositis (mouth/gut sores), organ injury, infertility or gonadal failure, and secondary cancers.

Navigating the Decision

Deciding on a transplant requires a detailed consultation with an experienced transplant hematologist and a specialized Leukodystrophy Center. The team will evaluate your physical strength, cognitive status, and specific variant to help you weigh the uncertain potential for stabilization against the profound risks of the procedure ^[7][5]. Seeking an independent second opinion is highly recommended.